替吉奥单药与XELOX方案一线治疗老年晚期胃癌的疗效比较

何广思; 蒋宗惠; 章敢

doi:10.13898/j.cnki.issn.1000-2200.2017.02.015

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

替吉奥单药与XELOX方案一线治疗老年晚期胃癌的疗效比较

何广思 , 蒋宗惠 , 章敢

文章导航 > 蚌埠医学院学报 > 2017, 42 > 2: (185-188)

引用本文:

Citation:

替吉奥单药与XELOX方案一线治疗老年晚期胃癌的疗效比较

安徽省滁州市第一人民医院肿瘤科, 239000

作者简介: 何广思(1983-),男,主治医师.

中图分类号: R735.2

Comparison of the curative effect of tegafur with XELOX program in the treatment of elderly patients with advanced gastric cancer

Department of Oncology, The First People's Hospital of Chuzhou, Chuzhou Anhui 239000, China
CLC number: R735.2

摘要: 目的：比较替吉奥单药与XELOX方案一线治疗老年晚期胃癌的疗效及不良反应。方法：将41例老年进展期胃癌患者随机分为单药组和联合化疗组。单药组20例，替吉奥单药口服，每次40～60 mg（体表面积<1.25 m²剂量为每次40 mg；体表面积为1.25～1.5 m²剂量为每次50 mg；体表面积>1.5 m²为每次60 mg），每天2次，连用14 d，每3周重复；联合化疗组21例，XELOX方案化疗，奥沙利铂130 mg/m²，静脉滴注3 h，第1天；卡培他滨1 000 mg/m²，每天2次，连服14 d，每3周重复。每用药2个周期后评价疗效。结果：单药组有效率30.0%、疾病控制率65.0%，中位无进展生存时间为5.6个月；联合化疗组有效率42.9%，疾病控制率66.7%，中位无进展生存时间为6.2个月。2组差异均无统计学意义（P>0.05）。联合化疗组的周围神经毒性发生率高于单药组（P<0.05），其他化疗不良反应发生率差异均无统计学意义（P>0.05）。结论：替吉奥单药治疗老年进展期胃癌可取得不弱于联合化疗方案的近期疗效，且有较低的不良反应。
- 胃肿瘤 /
- 替吉奥 /
- 奥沙利铂 /
- 卡培他滨
Abstract: Objective:To compare the curative effects and adverse reactions of Tijiao with XELOX program in the treatment of elderly patients with advanced gastric cancer.Methods:Forty-one elderly patients with advanced gastric cancer were randomly divided into the single drug group(20 cases)and combined chemotherapy group(21 cases).The single drug group were treated with the Tijiao by oral,twice a day for 14 days,repeated every 3 weeks(40 mg each time for the body surface area <1.25 m²,50 mg each time for the body surface area between 1.25 m² and 1.5 m² and 60 mg each time for the body surface area >1.5 m²).The combined chemotherapy group were treated with XELOX program,which included the 130 mg/m² of oxaliplatin by intravenous dripat first day for 3 hours combined with 1 000 mg/m² of capecitabineby oral,twice a day for 14 days,repeated every 3 weeks.The curative effects in two groups were evaluated after 2 cycles of treatment.Results:The effective rate,disease control rate and median progression-free(PFS) time in single drug group were 30%,65% and 5.6 months,respectively,the effective rate,disease control rate and median progression-free time in combined chemotherapy group were 42.9%,66.7% and 6.2 months,respectively,and the difference of which between two groupswas not statistically significant(P>0.05).The incidence rate of peripheral neurotoxicity in combined chemotherapy group was higher than that in single drug group(P<0.05),and the incidence of other adverse reactions between two groups was not statistically significant(P>0.05).Conclusions:The short-term curative effect of the Tijiao in treating advanced gastric cancer elderly patients is not worse than that of combination chemotherapy,and which has less adverse reaction.
- gastric neoplasms /
- tegafur /
- oxaliplatin /
- capecitabine

[1]	邹小农,孙喜斌,陈万青,等.2003-2007年中国胃癌发病与死亡情况分析[J].肿瘤,2012,32(2):104.
[2]	王会忠.不同化疗方案在晚期胃癌治疗中的临床效果比较[J].实用癌症杂志,2014,29(2):183.
[3]	张信强,徐燕,陈明祥.替吉奥胶囊单药联合放疗治疗晚期胃癌的临床观察[J].临床肿瘤学杂志,2013,18(7):628.
[4]	TOUGERON D,HAMIDOU H,SCOTTÉ M,et al.Esophageal cancer in the elderlyan analysis of the factors associated with treatment decisions and outcomes[J].BMC Cancer,2010,10:510.
[5]	LIU B,YING J,LUO C,et al.S-1 combined with oxaliplatin as first line chemotherapy for Chinese advanced gastric cancer patients[J].Hepatogastroenterology,2012,59(114):649.
[6]	KOIZUMI W,AKIYA T,SATO A,et al.PhaseⅡstudy of S-1 as first-line treatment for elderly patients over 75 years of age with advanced gastric cancerthe Tokyo Cooperative Oncology Group study[J].Cancer Chemother Pharmacol,2010,65(6):1093.
[7]	张洁,肖雅,陆明,等.卡培他滨单药或联合方案治疗晚期胃癌的临床研究[J].中华肿瘤杂志,2009,31(4):312.
[8]	杨武,喻永龙,朱西平,等.替吉奥和卡培他滨分别联合奥沙利铂化疗对晚期胃癌疗效观察[J].蚌埠医学院学报,2014,39(11):1512.
[9]	朱益平,盛莉莉,王潞,等.奥沙利铂联合卡培他滨或替吉奥治疗进展期胃癌的临床观察[J].肿瘤防治研究,2014,41(7):815.
[10]	KIM GM,JEUNG HC,RHA SY,et al.A randomized phaseⅡtrail of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer[J].Eur J Cancer,2012,48(4):518.

[1]	杨武 , 喻永龙 , 朱西平 , 张振华 . 替吉奥和卡培他滨分别联合奥沙利铂化疗对晚期胃癌疗效观察. 蚌埠医学院学报, 2014, 39(11): 1512-1514.
[2]	何峰 , 张小霞 . 奥沙利铂联合卡培他滨对胃癌患者的疗效及对免疫功能的影响. 蚌埠医学院学报, 2013, 37(9): 1096-1098,1102.
[3]	蒋祥德 , 王磊 , 刘友如 , 施朕善 , 徐莹 . 卡培他滨联合奥沙利铂、多西他赛一线治疗晚期胃癌临床观察. 蚌埠医学院学报, 2014, 38(4): 471-473.
[4]	翟云芝 , 郑荣生 . 奥沙利铂联合亚叶酸钙、氟尿嘧啶治疗晚期胃癌. 蚌埠医学院学报, 2005, 30(3): 249-250.
[5]	徐金发 , 潘明 , 鲍瑜 , 陈倩 . 奥沙利铂联合亚叶酸钙/氟尿嘧啶治疗晚期胃癌的临床观察. 蚌埠医学院学报, 2009, 34(5): 417-419.
[6]	李靖 , 郑旭薇 , 贾建光 , 郭晨旭 , 金鑫 , 钱军 . 人参皂苷Rh2对低浓度的奥沙利铂诱导人胃癌SGC-7901侧群细胞凋亡的增敏作用. 蚌埠医学院学报, 2018, 43(5): 561-566,572. doi: 10.13898/j.cnki.issn.1000-2200.2018.05.001
[7]	张贡献 , 杨洋 . 奥沙利铂甘露醇联合雷替曲塞在老年晚期胃癌中的疗效观察. 蚌埠医学院学报, 2015, 40(8): 1011-1013. doi: 10.13898/j.cnki.issn.1000-2200.2015.08.008
[8]	单宏杰 , 马骖 . 整合化疗治疗老年局部晚期胃癌的临床研究. 蚌埠医学院学报, 2020, 45(3): 348-350, 354. doi: 10.13898/j.cnki.issn.1000-2200.2020.03.017
[9]	张红宇 , 吴昌平 , 吴骏 , 周文杰 , 王琦 , 孟婕 . EOF与XELOX方案治疗晚期胃癌的疗效与不良反应比较. 蚌埠医学院学报, 2011, 36(12): 1325-1327.
[10]	杨燕 , 王明喜 , 汪子书 , 王俊斌 , 郑荣生 . 奥沙利铂联合吉西他滨治疗晚期原发性肝癌疗效观察. 蚌埠医学院学报, 2015, 40(9): 1158-1160. doi: 10.13898/j.cnki.issn.1000-2200.2015.09.005
[11]	韩啸 . 多西他赛联合奥沙利铂治疗晚期非小细胞肺癌34例临床观察. 蚌埠医学院学报, 2008, 33(5): 535-537.
[12]	孙翠玲 , 田添 , 高莹莹 , 胡文军 . 紫杉醇联合卡培他滨或氟尿嘧啶一线治疗晚期胃癌临床对照研究. 蚌埠医学院学报, 2016, 41(2): 194-196. doi: 10.13898/j.cnki.issn.1000-2200.2016.02.018
[13]	葛宁 , 詹必红 , 常娜 , 臧春宝 . 替吉奥联合伽马刀治疗食管癌腹膜后淋巴结转移的临床观察. 蚌埠医学院学报, 2015, 40(10): 1346-1349.
[14]	周燕 , 汪庚明 , 何泽来 , 张亚军 , 李红伟 , 景奇骏 . 替吉奥同步化疗联合放疗治疗老年食管癌的临床疗效分析. 蚌埠医学院学报, 2020, 45(7): 871-875. doi: 10.13898/j.cnki.issn.1000-2020.07.008
[15]	王影 . 康复新防治奥沙利铂所致周围神经毒性的效果观察. 蚌埠医学院学报, 2015, 40(4): 536-537. doi: 10.13898/j.cnki.issn.1000-2200.2015.04.041
[16]	郑中显 , 潘明 . 阿帕替尼联合替吉奥用于初始治疗失败后晚期肝癌的疗效及安全性分析. 蚌埠医学院学报, 2020, 45(7): 917-920. doi: 10.13898/j.cnki.issn.1000-2020.07.020
[17]	王有猛 , 阚庆生 . 奥沙利铂联合氟尿嘧啶/亚叶酸钙方案治疗晚期结直肠癌30例. 蚌埠医学院学报, 2010, 35(9): 926-927.
[18]	杨武 , 喻永龙 , 王新帅 , 朱西平 , 张振华 . 钙镁合剂和甲钴胺预防奥沙利铂所致神经毒性疗效比较. 蚌埠医学院学报, 2013, 37(1): 37-40.
[19]	高洁 , 丁淑琴 , 邓蓉 , 郭普 , 张伦军 , 黄桦 . 奥沙利铂通过p53信号通路抑制肝癌细胞增殖的机制研究. 蚌埠医学院学报, 2018, 43(8): 984-988. doi: 10.13898/j.cnki.issn.1000-2200.2018.08.002
[20]	王有猛 , 阚庆生 . 紫杉醇联合奥沙利铂治疗非小细胞肺癌疗效分析. 蚌埠医学院学报, 2010, 35(10): 1023-1024.

点击查看大图

计量

文章访问数: 3878
HTML全文浏览量: 618
PDF下载量: 69
被引次数: 0

替吉奥单药与XELOX方案一线治疗老年晚期胃癌的疗效比较

作者简介: 何广思(1983-),男,主治医师.

安徽省滁州市第一人民医院肿瘤科, 239000

收稿日期: 2016-03-04

关键词:

摘要: 目的：比较替吉奥单药与XELOX方案一线治疗老年晚期胃癌的疗效及不良反应。方法：将41例老年进展期胃癌患者随机分为单药组和联合化疗组。单药组20例，替吉奥单药口服，每次40～60 mg（体表面积<1.25 m²剂量为每次40 mg；体表面积为1.25～1.5 m²剂量为每次50 mg；体表面积>1.5 m²为每次60 mg），每天2次，连用14 d，每3周重复；联合化疗组21例，XELOX方案化疗，奥沙利铂130 mg/m²，静脉滴注3 h，第1天；卡培他滨1 000 mg/m²，每天2次，连服14 d，每3周重复。每用药2个周期后评价疗效。结果：单药组有效率30.0%、疾病控制率65.0%，中位无进展生存时间为5.6个月；联合化疗组有效率42.9%，疾病控制率66.7%，中位无进展生存时间为6.2个月。2组差异均无统计学意义（P>0.05）。联合化疗组的周围神经毒性发生率高于单药组（P<0.05），其他化疗不良反应发生率差异均无统计学意义（P>0.05）。结论：替吉奥单药治疗老年进展期胃癌可取得不弱于联合化疗方案的近期疗效，且有较低的不良反应。

English Abstract

Comparison of the curative effect of tegafur with XELOX program in the treatment of elderly patients with advanced gastric cancer

Department of Oncology, The First People's Hospital of Chuzhou, Chuzhou Anhui 239000, China

Received Date: 2016-03-04

Abstract: Objective:To compare the curative effects and adverse reactions of Tijiao with XELOX program in the treatment of elderly patients with advanced gastric cancer.Methods:Forty-one elderly patients with advanced gastric cancer were randomly divided into the single drug group(20 cases)and combined chemotherapy group(21 cases).The single drug group were treated with the Tijiao by oral,twice a day for 14 days,repeated every 3 weeks(40 mg each time for the body surface area <1.25 m²,50 mg each time for the body surface area between 1.25 m² and 1.5 m² and 60 mg each time for the body surface area >1.5 m²).The combined chemotherapy group were treated with XELOX program,which included the 130 mg/m² of oxaliplatin by intravenous dripat first day for 3 hours combined with 1 000 mg/m² of capecitabineby oral,twice a day for 14 days,repeated every 3 weeks.The curative effects in two groups were evaluated after 2 cycles of treatment.Results:The effective rate,disease control rate and median progression-free(PFS) time in single drug group were 30%,65% and 5.6 months,respectively,the effective rate,disease control rate and median progression-free time in combined chemotherapy group were 42.9%,66.7% and 6.2 months,respectively,and the difference of which between two groupswas not statistically significant(P>0.05).The incidence rate of peripheral neurotoxicity in combined chemotherapy group was higher than that in single drug group(P<0.05),and the incidence of other adverse reactions between two groups was not statistically significant(P>0.05).Conclusions:The short-term curative effect of the Tijiao in treating advanced gastric cancer elderly patients is not worse than that of combination chemotherapy,and which has less adverse reaction.